NASDAQ:IRMD iRadimed (IRMD) Stock Price, News & Analysis $82.31 -1.14 (-1.37%) Closing price 11/18/2026 04:00 PM EasternExtended Trading$82.32 +0.00 (+0.01%) As of 11/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About iRadimed Stock (NASDAQ:IRMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get iRadimed alerts:Sign Up Key Stats Today's Range$81.50▼$84.9750-Day Range$76.68▼$89.8352-Week Range$76.35▼$107.90Volume78,817 shsAverage Volume131,055 shsMarket Capitalization$1.05 billionP/E Ratio44.63Dividend Yield0.97%Price Target$120.00Consensus RatingBuy Company Overview iRadimed Corporation develops, manufactures and markets medical devices designed for use in magnetic resonance imaging (MRI) environments. Its products include MRI-compatible patient monitoring systems and intravenous infusion pumps, along with related accessories. The company’s monitoring systems help clinicians track patients during MRI procedures, while its infusion pumps deliver fluids and medications in the MRI suite. iRadimed’s equipment is designed to operate in the presence of MRI magnets, where conventional medical devices may not be suitable. Based in Winter Springs, Florida, iRadimed serves hospitals and other medical facilities in the United States and internationally. The company was founded in 2004 by Roger Susi, who has led its development of MRI-compatible medical equipment.AI Generated. May Contain Errors. Read More iRadimed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreIRMD MarketRank™: 3.31736035049 of 5 starsiRadimed scored higher than 66% of companies evaluated by MarketBeat, and ranked 493rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingBuy Consensus RatingiRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialiRadimed has a consensus price target of $120.00, representing about 45.8% upside from its current price of $82.31.Amount of Analyst CoverageiRadimed has only been the subject of 2 research reports in the past 90 days.Read more about iRadimed's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of iRadimed is 44.63, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.71.Price to Earnings Ratio vs. SectorThe P/E ratio of iRadimed is 44.63, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.36.Price to Book Value per Share RatioiRadimed has a P/B Ratio of 9.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted7.06% of the float of iRadimed has been sold short.Short Interest Ratio / Days to CoveriRadimed has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in iRadimed has recently decreased by 11.96%, indicating that investor sentiment is improving significantly. Dividend0.8 / 5Dividend StrengthWeak Dividend YieldiRadimed has a dividend yield of 0.96%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthiRadimed has only been increasing its dividend for 1 years.Dividend CoverageThe dividend payout ratio of iRadimed is 42.78%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about iRadimed's dividend. News and Social Media3.1 / 5News Sentiment0.96 News SentimentiRadimed has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for iRadimed this week, compared to 3 articles on an average week.Search Interest1 people have searched for IRMD on MarketBeat in the last 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $122,616.00 in company stock.Percentage Held by Insiders34.60% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about iRadimed's insider trading history. Receive IRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iRadimed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRMD Stock News HeadlinesIRadimed Earnings Call Highlights 3870 Growth MomentumNovember 16 at 11:41 AM | theglobeandmail.comIRADIMED (IRMD) Shares Moved, What Is Behind The Latest Attention?November 3, 2026 | finance.yahoo.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders. | Base Camp Trading (Ad)Is IRADIMED (IRMD) Fully Priced Based On Future Cash Flow?October 31, 2026 | finance.yahoo.comIradimed (IRMD) Q3 2026 Earnings Call TranscriptOctober 31, 2026 | finance.yahoo.comIRADIMED CORPORATION Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 30, 2026 | marketscreener.comMIradimed Posts Record Q3 Revenue, Eyes $100M Run RateOctober 30, 2026 | 247wallst.comIRadimed Q3 Non-GAAP Earnings, Revenue Increase; Q4 Outlook Issued, 2026 Guidance RevisedOctober 30, 2026 | finance.yahoo.comSee More Headlines IRMD Stock Analysis - Frequently Asked Questions How have IRMD shares performed this year? iRadimed's stock was trading at $97.28 at the beginning of the year. Since then, IRMD stock has decreased by 15.4% and is now trading at $82.31. How were iRadimed's earnings last quarter? iRadimed Corporation (NASDAQ:IRMD) posted its quarterly earnings data on Friday, October, 30th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.55. The medical equipment provider had revenue of $24.20 million for the quarter, compared to the consensus estimate of $23.47 million. iRadimed had a net margin of 26.85% and a trailing twelve-month return on equity of 23.90%. Read the conference call transcript. When did iRadimed IPO? iRadimed (IRMD) raised $13 million in an initial public offering (IPO) on Wednesday, July 16th 2014. The company issued 2,016,000 shares at $6.25 per share. Who are iRadimed's major shareholders? Top institutional investors of iRadimed include Copeland Capital Management LLC (2.99%), State Street Corp (1.86%), Goldman Sachs Group Inc. (1.65%) and Bridge City Capital LLC (0.76%). Insiders that own company stock include Roger E Susi, James B Hawkins, Monty K Allen and John Glenn. View institutional ownership trends. How do I buy shares of iRadimed? Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of iRadimed own? Based on aggregate information from My MarketBeat watchlists, some other companies that iRadimed investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Intel (INTC), Alphabet (GOOG), Tesla (TSLA) and Pfizer (PFE). Company Calendar Record date for 8/28 Dividend8/14/2026Ex-Dividend for 8/28 Dividend8/14/2026Dividend Payable8/28/2026Last Earnings10/30/2026Record date for 11/27 Dividend11/13/2026Ex-Dividend for 11/27 Dividend11/13/2026Today11/18/2026Dividend Payable11/27/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, IRMD's financial health has been in the Red zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:IRMD CIK1325618 Webwww.iradimed.com Phone(407) 677-8022Fax407-677-5037Employees166Year Founded2004Price Target and Rating Average Price Target for iRadimed$120.00 High Price Target$120.00 Low Price Target$120.00 Potential Upside/Downside+45.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)$1.87 Trailing P/E Ratio44.63 Forward P/E RatioN/A P/E GrowthN/ANet Income$22.48 million Net Margins26.85% Pretax Margin34.83% Return on Equity23.90% Return on Assets20.89% Debt Debt-to-Equity RatioN/A Current Ratio8.99 Quick Ratio7.68 Sales & Book Value Annual Sales$83.81 million Price / Sales12.56 Cash Flow$1.83 per share Price / Cash Flow44.90 Book Value$8.32 per share Price / Book9.89Miscellaneous Outstanding Shares12,790,000Free Float8,363,000Market Cap$1.05 billion OptionableOptionable Beta0.91 Social Links Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:IRMD) was last updated on 11/18/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iRadimed Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share iRadimed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.